• JZL184: A Benchmark Monoacylglycerol Lipase Inhibitor for En

  2026-07-10

  JZL184 is a potent and selective monoacylglycerol lipase inhibitor that elevates brain 2-AG, modulates endocannabinoid signaling, and enables precise CB1 receptor studies. It is widely adopted in neuropharmacology and pain research due to its validated specificity and well-characterized protocol parameters.

• CXCR4-Targeted Theranostics in Lymphoma: Imaging and Precisi

  2026-07-09

  This review synthesizes recent advances in CXCR4-targeted imaging and therapeutic strategies for lymphoma, focusing on the role of CXCR4 as a biomarker and therapeutic target. The findings highlight how peptide and small-molecule ligands enable both precise diagnosis and targeted intervention, while also addressing translational challenges such as off-target effects and resistance mechanisms.

• Phytol in Nuclear Receptor Signaling: Protocols & Nanomateri

  2026-07-09

  Phytol stands out as a dual-modality reagent—enabling both refined RXR-driven transcriptional studies and the blossoming of advanced nanomaterial platforms. This article delivers stepwise workflows, key troubleshooting techniques, and cross-domain insights to unlock robust, reproducible results with Phytol.

• LGK-974: Precision PORCN Inhibition in Wnt-Driven Cancer Res

  2026-07-08

  This thought-leadership article bridges developmental biology insights and translational oncology, articulating why LGK-974, a potent and highly specific PORCN inhibitor, is pivotal for researchers investigating Wnt signaling in cancer. By integrating mechanistic rationale, evidence from both developmental and preclinical models, and strategic guidance for experimental workflows, the piece uniquely positions APExBIO’s LGK-974 as a next-generation tool for dissecting Wnt-driven pathologies, with a dedicated focus on RNF43-mutant pancreatic cancer and beyond.

• Cy5.5 NHS Ester: Precision Labeling for Translational Innova

  2026-07-08

  This thought-leadership article explores how Cy5.5 NHS ester (non-sulfonated) enables next-generation translational research, particularly in the context of complex disease modeling and advanced in vivo imaging. We synthesize mechanistic insight, experimental protocols, and strategic guidance—anchored to the latest evidence on senescence-targeted therapies and the evolving needs of translational scientists.

• CXCR4-Targeted Theranostics in Lymphoma: Imaging and Therapy

  2026-07-07

  This review highlights recent advances in CXCR4-targeted imaging and therapeutic strategies for lymphoma, focusing on the integration of molecular imaging ligands and precision therapies. The findings emphasize the clinical potential of CXCR4 inhibition for improving diagnostic accuracy and sensitizing malignant cells to treatment.

• Mecamylamine Hydrochloride: Decoding nAChR Antagonism in Tra

  2026-07-07

  Explore the advanced neuropharmacology of Mecamylamine hydrochloride as a non-competitive nAChR antagonist, highlighting its unique role in dissecting gut-brain cholinergic signaling and neuropsychiatric disorder mechanisms. This article unveils new translational insights and practical guidance for precise assay design.

• CXCR4-Targeted Theranostics in Lymphoma: Precision Imaging &

  2026-07-06

  This review highlights recent advances in CXCR4-targeted imaging and therapeutic strategies for lymphoma, emphasizing the integration of molecular diagnostics and precision therapy. The paper details the mechanisms by which CXCR4 overexpression drives lymphoma progression and explores the clinical and experimental value of peptide- and small-molecule-based CXCR4 inhibitors and imaging agents.

• Sex Differences in Angiotensin II-Induced Hypertension in Mi

  2026-07-06

  The reference study pioneers a systematic analysis of sex-dependent responses to angiotensin II-induced hypertension in conscious mice, revealing that male mice develop significantly greater hypertension than females. By integrating telemetry and hormonal manipulation, the study clarifies the protective roles of female sex hormones and the resetting of baroreflex control, with broad implications for preclinical cardiovascular research.

• CCCP in Translational Research: From Mechanism to Biomarker

  2026-07-05

  Explore how CCCP (carbonyl cyanide m-chlorophenyl hydrazine) is transforming mitochondrial research, powering translational workflows, and enabling non-invasive biomarker discovery for neurodegenerative disease. This article integrates mechanistic detail, protocol strategy, and deep learning–driven innovation, offering researchers a competitive roadmap beyond standard product summaries.

• Polymyxin B (Sulfate): A Systems Approach to Multidrug-Resis

  2026-07-04

  Explore Polymyxin B sulfate as a precision tool for multidrug-resistant Gram-negative infection research, with an emphasis on resistance gene dynamics and translational assay design. This article provides a systems-level perspective distinct from standard protocol guides.

• Integrated Omics Dissects XFZYD Mechanisms in Chronic Migrai

  2026-07-03

  This study employs integrated metabolomics and transcriptomics to uncover how Xuefu Zhuyu Decoction (XFZYD) treats nitroglycerin-induced chronic migraine in rats, focusing on its reversal of blood stasis and modulation of the MAPK/ERK pathway. The findings provide a multidimensional molecular basis for XFZYD's clinical efficacy and highlight targets for future migraine therapies.

• Hydrocortisone in Applied Research: Glucocorticoid Hormone W

  2026-07-03

  Hydrocortisone stands out as a benchmark glucocorticoid hormone for dissecting anti-inflammatory pathways, barrier function, and stress response in diverse preclinical models. This guide delivers actionable protocols, advanced troubleshooting, and insight into how the latest research on RNA regulation can shape experimental design using APExBIO’s high-purity Hydrocortisone.

• Bile Acid Metabolism Subtypes Reveal Prognostic CRC Markers

  2026-07-02

  Feng et al. (2026) introduced a molecular subtyping strategy for colorectal cancer (CRC) based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as markers of immune dysfunction and prognosis. Their integrative analysis connects metabolic state with tumor immune microenvironment, informing biomarker-driven stratification and therapeutic approaches.

• Talabostat Mesylate (PT-100): Protocols & Innovations in DPP

  2026-07-02

  Talabostat mesylate (PT-100) stands out for its precision in inhibiting DPP4 and FAP, making it a cornerstone for tumor microenvironment and immune modulation research. This article demystifies advanced workflows, highlights troubleshooting strategies, and bridges new findings in inflammasome regulation to optimize experimental outcomes.

455 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page